Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology and pharmaceutical subgroups have a combined weight of ~97.5% of IBB’s portfolio. The moving average provides investors with a ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback